Deals
GSK to Sell Remaining $1.6 Billion Stake in Haleon
- Sale will complete separation from consumer health company
- Drugmaker has raised nearly $5 billion from Haleon share sales
This article is for subscribers only.
GSK Plc will sell its remaining stake in Haleon Plc for £1.25 billion ($1.6 billion), completing the drugmaker’s separation from the consumer health company.
About 385 million shares will be sold at a price of 324 pence each, the UK pharma company said Friday. The sale, through a placing with institutional investors, represents a roughly 4.2% holding in the maker of Sensodyne toothpaste.